LYR-210 for Chronic Rhinosinusitis
Our lead product candidate, entering Phase 2, is LYR-210 for chronic rhinosinusitis (CRS).
LYR-210 uses Lyra’s transmucosal therapeutic system to deliver a custom long-acting formulation of an approved, proven steroid, mometasone furoate, deep into the sinonasal tissues that are difficult to access with conventional therapeutic approaches.
LYR-210 has been designed to be placed directly into inflamed sinonasal passages of pre-surgical patients and release topical steroid anti-inflammatory therapy for up to six months. With its innovative design, LYR-210 can be administered by a physician in a routine office visit.
In Phase 1 clinical testing, LYR-210 was shown to be safe and well-tolerated and demonstrated significant improvements in clinical outcomes in patients with CRS. LYR-210 was successfully administered to CRS patients both with and without nasal polyps.
LYR-210 has the potential to be one of the first approved drug products for CRS and is the only product in development offering six months of drug therapy with a single administration.